Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
- PMID: 9738049
- PMCID: PMC105093
- DOI: 10.1128/JCM.36.10.2950-2956.1998
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
Abstract
The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 against 83 isolates of Acremonium strictum, Aspergillus flavus, Aspergillus fumigatus, Aspergillus terreus, Bipolaris spp., Blastomyces dermatitidis, Cladophialophora bantiana, Fusarium oxysporum, Fusarium solani, Histoplasma capsulatum, Phialophora spp., Pseudallescheria boydii, Rhizopus arrhizus, Scedosporium prolificans, and Sporothrix schenckii were compared. The in vitro activities of these agents against 104 isolates of yeast pathogens of Candida spp., Cryptococcus neoformans, and Trichosporon beigelii were also compared. MICs were determined by following a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NCCLS) for broth microdilution testing of the filamentous fungi (visual MICs) and the NCCLS M27-A broth microdilution method for yeasts (both visual and turbidimetric MICs). The in vitro fungicidal activity of SCH56592 was superior (minimum fungicidal concentrations [MFCs], 0.25 to 4 microgram/ml for 7 of 18 species tested) to those of MK-0991 and LY303366 (MFCs, 8 to >16 microgram/ml for all species tested) for the molds tested, but the echinocandins had a broader spectrum of fungicidal activity (MFCs at which 90% of strains are inhibited [MFC90s], 0.5 to 4 microgram/ml for 6 of 9 species tested) than SCH56592 (MFC90s, 0.25 to 8 microgram/ml for 4 of 9 species tested) against most of the yeasts tested. Neither echinocandin had in vitro activity (MICs, >16 microgram/ml) against C. neoformans and T. beigelii, while the SCH56592 MICs ranged from 0.12 to 1.0 microgram/ml for these two species. The MICs of the three agents for the other species ranged from <0.03 to 4 microgram/ml. These results suggest that these new agents have broad-spectrum activities in vitro; their effectiveness in the treatment of human mycoses is to be determined.
Similar articles
-
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.J Clin Microbiol. 1998 Jan;36(1):198-202. doi: 10.1128/JCM.36.1.198-202.1998. J Clin Microbiol. 1998. PMID: 9431946 Free PMC article.
-
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.Diagn Microbiol Infect Dis. 1998 Apr;30(4):251-5. doi: 10.1016/s0732-8893(97)00246-0. Diagn Microbiol Infect Dis. 1998. PMID: 9582584
-
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Rev Iberoam Micol. 2003 Dec;20(4):121-36. Rev Iberoam Micol. 2003. PMID: 15456349 Review.
-
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.Antimicrob Agents Chemother. 2006 Mar;50(3):917-21. doi: 10.1128/AAC.50.3.917-921.2006. Antimicrob Agents Chemother. 2006. PMID: 16495251 Free PMC article.
-
Laboratory evaluation of new antifungal agents against rare and refractory mycoses.Curr Opin Infect Dis. 2002 Dec;15(6):575-82. doi: 10.1097/00001432-200212000-00004. Curr Opin Infect Dis. 2002. PMID: 12821833 Review.
Cited by
-
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Haematologica. 2013 Apr;98(4):492-504. doi: 10.3324/haematol.2012.065110. Epub 2012 Sep 14. Haematologica. 2013. PMID: 22983580 Free PMC article. Review.
-
Clinical and laboratory update on blastomycosis.Clin Microbiol Rev. 2010 Apr;23(2):367-81. doi: 10.1128/CMR.00056-09. Clin Microbiol Rev. 2010. PMID: 20375357 Free PMC article. Review.
-
In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.Antimicrob Agents Chemother. 2004 Sep;48(9):3217-25. doi: 10.1128/AAC.48.9.3217-3225.2004. Antimicrob Agents Chemother. 2004. PMID: 15328076 Free PMC article. Review. No abstract available.
-
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.Antimicrob Agents Chemother. 2008 Jan;52(1):321-8. doi: 10.1128/AAC.00699-07. Epub 2007 Oct 15. Antimicrob Agents Chemother. 2008. PMID: 17938191 Free PMC article.
-
Efficacy of posaconazole in a murine model of central nervous system aspergillosis.Antimicrob Agents Chemother. 2004 Oct;48(10):4063-6. doi: 10.1128/AAC.48.10.4063-4066.2004. Antimicrob Agents Chemother. 2004. PMID: 15388482 Free PMC article.
References
-
- Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis. 1992;14:S43–S53. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous